Skip to main content
SpringerLink
Log in

Phosphodiesterase-4B-Inhibitor zur Behandlung der idiopathischen Lungenfibrose (IPF)

Phosphodiesterase 4B inhibitor for the treatment of idiopathic pulmonary fibrosis

  • Journal Club
  • Published:
Zeitschrift für Pneumologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Hostettler K (2016) Idiopathische Lungenfibrose – Pathogenese und therapeutische Konzepte. Ther Umsch 73(1):19–24

    PubMed  Google Scholar 

  2. Raghu G, Remy-Jarin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 205:e18–e47

    PubMed  Google Scholar 

  3. Heng L, Jianping Z, Wei T (2018) Phosphodiesterase‑4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol 9:1048

    Google Scholar 

  4. Schick MA, Schlegel N (2022) Clinical implication of Phosphodiesterase-4-inhibition. Int J Mol Sci 23(3):1209

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Med. Klinik III (Klinik für Lungen- und Bronchialheilkunde), Kreiskliniken Reutlingen, Steinenberg Str. 31, 72764, Reutlingen, Deutschland

    A. Gillissen

Authors
  1. A. Gillissen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gillissen.

Ethics declarations

Interessenkonflikt

A. Gillissen gibt an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gillissen, A. Phosphodiesterase-4B-Inhibitor zur Behandlung der idiopathischen Lungenfibrose (IPF). Z Pneumologie 19, 387–388 (2022). https://doi.org/10.1007/s10405-022-00470-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-022-00470-0

Search

Navigation